- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate clinically significant FVIII inhibitor development in a large number of severe hemophila A patients treated with ReFacto AF in usual use settings.
Critère d'inclusion
- Severe haemophilia A (FVIII:C <1%) in male patients ≥12 years of age with a treatment history of >150 EDs to prior recombinant or plasma-derived FVIII replacement products and transitioning to ReFacto AF from ReFacto or other recombinant or plasma-derived FVIII replacement products